^
    Evidence Level:
    Sensitive: C3 – Early Trials

    [CDKN2A mutation-Squamous Cell Carcinoma of Head and Neck-palbociclib]

    Source:
    ASCO 2023
    Test:

    FoundationOne® CDx, Tempus xT Assay

    Title:
    Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.
    Published date:
    05/25/2023
    Excerpt:
    The primary aims of this single-arm, phase 2 trial were to determine the objective response rate (ORR) of HPV-negative, LA-HNSCC to palbociclib, and to correlate responses to somatic CDKN2A alterations....The ORR with palbociclib was significantly higher in CDKN2A altered disease.
    DOI:
    10.1200/JCO.2023.41.16_suppl.6015
    Trial ID:
    Los Tres Paso